Top

Published in:

Open Access 01-12-2016 | Research

High CHI3L1 expression is associated with glioma patient survival

Authors: Giedrius Steponaitis, Daina Skiriutė, Arunas Kazlauskas, Ieva Golubickaitė, Rytis Stakaitis, Arimantas Tamašauskas, Paulina Vaitkienė

Published in: Diagnostic Pathology | Issue 1/2016

Abstract

Background

Survival of glioma patients with the same tumor histology and grade can vary significantly, and some low-grade gliomas transform to a more malignant phenotype. There is a need of molecular signatures, which are better predictors of the patient diagnosis, outcome of treatment, and prognosis than the diagnosis provided by histopathology. We propose CHI3L1 mRNA expression as a prognostic biomarker for patients with glioma.

Methods

We measured CHI3L1 expression with quantitative real time-polymerase chain reaction (qRT-PCR) in the cohort of 98 patients with different grade glioma: 10 grade I pylocytic astrocytomas, 30 grade II diffuse astrocytomas, 20 grade III anaplastic astrocytomas, and 38 grade IV astrocytomas (glioblastomas). Statistical analyses were conducted to investigate the association between CHI3L1 mRNA expression levels and patient clinical variables.

Results

We demonstrated that mRNA expression of CHI3L1 was evidently higher in glioblastoma than in lower grade glioma tissues. We evaluated correlations between CHI3L1 expression, clinicopathological characteristics, and the outcomes of the patients. Patients with high CHI3L1 expression had a shorter overall survival (p < 0.001).

Conclusions

Findings presented in our study showed that increased mRNA level of CHI3L1 could be associated with the progression of astrocytoma and poor patient survival not only for glioblastoma, but for lower grade astrocytoma tumors as well. Further investigation will be required to evaluate CHI3L1 value as a molecular marker for astrocytoma prognoses and for novel treatment strategies against all grade astrocytomas.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi:10.1007/s00401-007-0243-4.CrossRefPubMedPubMedCentral

Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 2010;12(1):49–57. doi:10.1093/neuonc/nop007.CrossRefPubMedPubMedCentral

Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157–73. doi:10.1016/j.ccr.2006.02.019.CrossRefPubMed

Westphal M, Lamszus K. Circulating biomarkers for gliomas. Nat Rev Neurol. 2015;11(10):556–66. doi:10.1038/nrneurol.2015.171.CrossRefPubMed

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, et al. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro-Oncology. 2011;13(11):1244–51. doi:10.1093/neuonc/nor117.CrossRefPubMedPubMedCentral

Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol. 2009;5(7):1065–82. doi:10.2217/fon.09.66.CrossRefPubMed

Chiang YC, Lin HW, Chang CF, Chang MC, Fu CF, Chen TC, et al. Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma. Oncotarget. 2015.

Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Can Res. 2006;12(19):5698–704. doi:10.1158/1078-0432.CCR-06-0181.CrossRef

Sakamoto F, Katakami N, Kaneto H, Yasuda T, Takahara M, Miyashita K, et al. Association of serum YKL-40 levels with urinary albumin excretion rate in young Japanese patients with type 1 diabetes mellitus. Endocr J. 2013;60(1):73–9.CrossRefPubMed

10.

Kazakova M, Batalov A, Deneva T, Mateva N, Kolarov Z, Sarafian V. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis. Rheumatol Int. 2013;33(2):341–6. doi:10.1007/s00296-012-2387-3.CrossRefPubMed

11.

Hogdall EV, Ringsholt M, Hogdall CK, Christensen IJ, Johansen JS, Kjaer SK, et al. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer. 2009;9:8. doi:10.1186/1471-2407-9-8.CrossRefPubMedPubMedCentral

12.

Wang D, Zhai B, Hu F, Liu C, Zhao J, Xu J. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One. 2012;7(12):e51127. doi:10.1371/journal.pone.0051127.CrossRefPubMedPubMedCentral

13.

Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005;65(5):1678–86. doi:10.1158/0008-5472.CAN-04-2921.CrossRefPubMed

14.

Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 2002;62(15):4364–8.PubMed

15.

Shao R, Taylor SL, Oh DS, Schwartz LM. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget. 2015;6(38):40507-18. doi:10.18632/oncotarget.5943.

16.

Serao NV, Delfino KR, Southey BR, Beever JE, Rodriguez-Zas SL. Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genet. 2011;4:49. doi:10.1186/1755-8794-4-49.

17.

Boisselier B, Marie Y, El Hallani S, Kaloshi G, Iershov A, Kavsan V, et al. No association of (−131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis. J Neuro-Oncol. 2009;94(2):169–72. doi:10.1007/s11060-009-9817-4.CrossRef

18.

Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Can Res. 2005;11(9):3326–34. doi:10.1158/1078-0432.CCR-04-1765.CrossRef

19.

Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25(16):2288–94. doi:10.1200/JCO.2006.08.0705.CrossRefPubMed

20.

Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol. 2010;3(3):226–37.PubMedPubMedCentral

21.

Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, et al. Identification of genes differentially expressed in glioblastoma versus pilocytic Astrocytoma using suppression subtractive hybridization. Oncogene. 2006;25(19):2818–26. doi:10.1038/sj.onc.1209305.CrossRefPubMed

22.

Shostak K, Labunskyy V, Dmitrenko V, Malisheva T, Shamayev M, Rozumenko V, et al. HC gp-39 gene is upregulated in glioblastomas. Cancer Lett. 2003;198(2):203–10.CrossRefPubMed

23.

Celik C, Abali R, Guzel S, Bastu E, Kucukyalcin V, Yilmaz M. Elevated circulating levels of YKL-40 are a marker of abnormal glucose tolerance in women with polycystic ovary syndrome. Clin Endocrinol. 2012;77(6):893–7. doi:10.1111/j.1365-2265.2012.04437.x.CrossRef

24.

Turkyilmaz AK, Devrimsel G, Kirbas A, Cicek Y, Karkucak M, Capkin E, et al. Relationship between pulse wave velocity and serum YKL-40 level in patients with early rheumatoid arthritis. Rheumatol Int. 2013;33(11):2751–6. doi:10.1007/s00296-013-2810-4.CrossRefPubMed

25.

Sun L, Liu JY, Li LR. Serum YKL-40 levels are associated with type 2 diabetes mellitus in patients with obstructive sleep apnea syndrome. Genet Mol Res. 2015;14(3):8919–25. doi:10.4238/2015.August.3.15.CrossRefPubMed

26.

Castells X, Acebes JJ, Majos C, Boluda S, Julia-Sape M, Candiota AP, et al. Robustness of equations that define molecular subtypes of glioblastoma tumors based on five transcripts measured by RT-PCR. OMICS. 2015;19(1):41–51. doi:10.1089/omi.2014.0077.CrossRefPubMedPubMedCentral

Title: High CHI3L1 expression is associated with glioma patient survival
Authors: Giedrius Steponaitis
Daina Skiriutė
Arunas Kazlauskas
Ieva Golubickaitė
Rytis Stakaitis
Arimantas Tamašauskas
Paulina Vaitkienė
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2016
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-016-0492-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

High CHI3L1 expression is associated with glioma patient survival

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report

Retraction note: Down-regulation of microRNA-26a and up-regulation of microRNA-27a contributes to aggressive progression of human osteosarcoma

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant

Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report

Congenital atrophic dermatofibrosarcoma protuberans detected by COL1A1-PDGFB rearrangement